Loading
Ottobock SE & Co. KGaA Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 01 Apr 2026.
Ottobock SE & Co. KGaA: what insiders have been doing
Every trade that managers of Ottobock SE & Co. KGaA disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Duderstadt, Germany. It was founded in 1919. The last twelve months, up to 18 October 2026, brought 3 filings signed by 3 insiders.
Not one open-market sale was filed. On the buying side, 2 insiders reported 2 purchases totalling €107k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €54k, bought by Kaschke, Sylvia and made public on 30 March 2026 (0.0014% of market cap). On the buying side, the filings list 1 senior executive among the declarants.
With 3 filings in twelve months, the company is quieter than the median of 5 filings across the 287 companies we follow on the same exchange. Our records for Ottobock SE & Co. KGaA go back to 2025, with 12 purchases and 1 sale on the open market in total.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 1 April 2026, 199 days ago. Filings reach the BaFin feed a median of 4 days after the trade. The legal deadline for notifying a trade is three business days (MAR article 19).
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from BaFin. Past trades are no guide to future returns.
Insider Decl.
17
Thresholds
n/a
Buy Volume
€2M
12 ops. · all time
Sell Volume
€602M
1 ops. · all time
Who traded when
BuySaleOliver Jakobi2 buys
Andreas Spielmann1 buy
Arne Jörn1 buy
Dr. Arne Kreitz1 buy
Dr. Bernd Bohr1 buy
Dr. Joachim Kreuzburg1 buy
+6 other insiders
Since the insiders bought
- +3.3%Entry €52.10 · Close at T+90 €53.80
- -5.2%Entry €53.60 · Close at T+90 €50.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ottobock SE & Co. KGaA Strong Buy (bullish), based on 8 analysts. Average price target: €80.38.
Fundamental score
Ranked 7,299 of 24,148 companies
61.4
score / 100
Value58
Quality65
FCF yld6.9%
Earn yld2.8%
EV/EBITDA11.3x
ROE40%
Gross mgn53%
Net mgn5.4%
Debt/EBITDA2.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€50.90
Analyst consensus
8 analystsStrong buy
€66.00Target €80.38(+58%)€88.00
Income statement
Revenue€1.7B
Gross profit€886.5M53% margin
EBITDA€381.3M23% margin
Net income€90.2M7.4% margin
Valuation
PER (trailing)25.1x
PER (forward)14.0x
P/Book8.2x
Balance sheet & cash
Market cap€3.3B
Total debt€1.1B
Free Cash Flow€224.5M
Debt / Equity321%
Profitability & ownership
ROE39.9%
ROA8.8%
% insiders82.4%
% institutions11.7%
Last declaration on 1 April 2026
Declarations17 total
1,000 shares@ €53.050.0013% mcap9.6% of flowShareTradegateISIN DE000BCK2223BAFIN:40029813-3a013000327f
Canonical exit: 28 Jun 2026 (T+90)
1,000 shares@ €54.250.0014% mcap100.0% of flowShareStuttgartISIN DE000BCK2223BAFIN:40029813-d541d664b61c
Canonical exit: 23 Jun 2026 (T+90)
593,825 shares@ €66.006.1% of flowShareISIN DE000BCK2223BAFIN:40029813-50381d1023db
7,575 shares@ €66.0090.4% of flowShareISIN DE000BCK2223BAFIN:40029813-1bfdc19f98d4
Canonical exit: 5 Jan 2026 (T+90)
6,060 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-aa623e3f3ba5
Canonical exit: 5 Jan 2026 (T+90)
9,125,000 shares@ €66.0093.9% of flowShareISIN DE000BCK2223BAFIN:40029813-9ab07b487096
1,515 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-e46a48b7235f
Canonical exit: 5 Jan 2026 (T+90)
1,515 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-8e64efab0629
Canonical exit: 5 Jan 2026 (T+90)
2,272 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-1aadcf5d2a38
Canonical exit: 5 Jan 2026 (T+90)
4,545 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-f8c7619405d7
Canonical exit: 5 Jan 2026 (T+90)
1,515 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-ce531fb71a6f
Canonical exit: 5 Jan 2026 (T+90)
3,030 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-35d5f2eaa4ea
Canonical exit: 5 Jan 2026 (T+90)
1,515 shares@ €66.00100.0% of flowShareISIN DE000BCK2223BAFIN:40029813-68df3a0b35a8
Canonical exit: 5 Jan 2026 (T+90)
ShareISIN DE000BCK2223BAFIN:40029813
ShareISIN DE000BCK2223BAFIN:40029813-5f95a5f0ed93-2
ShareISIN DE000BCK2223BAFIN:40029813-5f95a5f0ed93
17 of 17 declarations
About Ottobock SE & Co. KGaA
Ottobock SE & Co. KGaA is a German medtech and human-bionics company listed on Xetra/Frankfurt (DAX/MDAX/SDAX), in Germany. The group is best known for its leadership in prosthetics, orthotics, rehabilitation products and related digital and bionic mobility solutions. Its roots go back to Otto Bock’s founding of the business in 1919, and the company later established its long-term operational base in Duderstadt, where its headquarters are now located. Ottobock expanded internationally early on, including the establishment of its first U.S. subsidiary in Minneapolis in 1958. Since 2018, the company has operated as Ottobock SE & Co. KGaA, a structure designed to support long-term growth while preserving the family’s strategic influence.
Ottobock’s business model is centered on two core segments. The first, Products & Components (B2B), includes prosthetics components and solutions, neuro-orthotics, digital orthotics and prosthetics, and bionic exoskeletons. The second, Patient Care (B2C), covers a global network of roughly 400 orthopedic patient care centers, where the company provides treatment and user support directly to patients. This dual model gives Ottobock a differentiated position across both industrial medtech supply and clinical care delivery. It also strengthens customer relationships, creates recurring touchpoints with practitioners, and supports a brand built on technical expertise, product performance and innovation.
Read moreShow less
From a competitive standpoint, Ottobock is widely positioned as a global leader in several high-barrier niches, especially advanced prosthetics, neuro-orthotics and human-bionics solutions. Its offering is anchored by a broad portfolio of premium products and services, including components, sockets, knees, hands, wheelchairs, rehabilitation products and exoskeleton technologies. Recent product initiatives have included Speedhand Solution, the next generation of the Exopulse Suit and the active Volton exoskeleton. The group continues to invest in R&D and selected strategic investments, reinforcing its innovation pipeline and supporting future product cycles. Geographically, Ottobock has a broad international footprint, with meaningful activity in Europe, North America and other major healthcare markets.
Recent news underscores the company’s momentum. For 2025, Ottobock reported stronger revenue and improved profitability, helped by new product launches, acquisitions and expanding reimbursement coverage in certain markets. The company also stated that it has been listed in the Prime Standard since 9 October 2025 and has been part of the SDAX and TecDAX since the end of 2025. For international equity investors, Ottobock offers exposure to the healthcare technology theme, with a blend of structural growth, innovation-led execution and a German listed profile on the Frankfurt market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
